Letter to the Editor

International Journal of Impotence Research (2006) 18, 411. doi:10.1038/sj.ijir.3901451

Response to Tomsak, R. PDE5 inhibitors and permanent visual loss (Int J Impot Res 2005; 17: 547–549)

S J Watt1, P Primatesta1 and R Siegel2

  1. 1Pfizer Ltd, Kent, UK
  2. 2Pfizer Pharmaceuticals Group, New York, NY, USA

Correspondence: S J Watt, E-mail: Stephen.Watt@Pfizer.com

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

Extra navigation

.

naturejobs

ADVERTISEMENT